Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Breast Neoplasms 273Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 181Neoplasms 174Lung Neoplasms 137Multiple Myeloma 136Neoplasm Metastasis 101Colorectal Neoplasms 100Melanoma 87Ovarian Neoplasms 80Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 73Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Recurrence 56Urinary Bladder Neoplasms 55Hematologic Neoplasms 55Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 51Lymphoma, Follicular 48Glioblastoma 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Sarcoma 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Cancer Extensive Stage × 90 days × Clear all
NCT05680922 2026-03-24

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Legend Biotech USA Inc

Phase 1 Active not recruiting
41 enrolled
EndocrineNETThoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡